ArticleInvestigational new drugs2024

A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas.

Randeep Sangha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.